Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults
Open Access
- 27 April 2026
- journal article
- Published by Springer Nature in Leukemia
- Vol. 40 (7) , 1411-1426
Abstract
Acquired aplastic anemia (AA) can present similarly to inherited bone marrow failure syndromes (IBMFS) but treatment differs. AA diagnosis relies on excluding IBMFS; however, genetic testing is not always available, may delay care or be inconclusive. We developed the Predictive Aplastic Score System (PASS), a clinical tool using readily available data to distinguish AA from IBMFS in adults. The training cohort included 212 adults (162 AA, 50 IBMFS). Compared to IBMFS, AA patients were older and more likely to have acute-onset, severe cytopenias. Using logistic regression with LASSO, we selected seven clinical variables for model inclusion: severity, acuity, age, IBMFS red flags, AA-associated conditions, AA-associated somatic changes, and telomere lengths. The model achieved AUC of 0.990 (95% CI: 0.982–0.999), with 100% positive predictive value (PPV) for AA for scores ≥30. 86.8% of patients with scores <0 had IBMFS. We validated PASS in 716 patients from four external cohorts with AUC of 0.977 (95% CI: 0.968–0.987). Threshold analysis confirmed 100% PPV for scores ≥30, rapidly diagnosing 80% of AA cases. PASS is a practical and accurate clinical tool that can rapidly distinguish AA from IBMFS for most adult patients. To promote clinical adoption, we developed an open-access web calculator ( https://pennmedicine.shinyapps.io/passcalc/ ).Keywords
All Related Versions
Funding Information
- U.S. Department of War (HT94252410445)
- National Heart, Lung, and Blood Institute (R01HL174612)
- National Heart, Lung, and Blood Institute (R38HL150214)
- American Society of Hematology (ASH HIP Fellow Award)
This publication has 54 references indexed in Scilit:
- Recursive Partitioning to Differentiate Acquired From Inherited Bone Marrow Failure SyndromesAmerican Journal of Hematology, 2025
- Fanconi Anemia and Other Hereditary Bone Marrow Failure Syndromes2024
- Acquired Bone Marrow Failure: Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria2024
- Diagnosis of immune pathophysiology in patients with bone marrow failureInternational Journal of Hematology, 2023
- First-line immunosuppressive therapy with rATG and CsA for severe aplastic anemia: 15 years’ experienceAnnals of Hematology, 2022
- Long-term outcomes of 172 children with severe aplastic anemia treated with rabbit antithymocyte globulin and cyclosporineAnnals of Hematology, 2020
- First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001‐2012American Journal of Hematology, 2018
- Genetic predisposition syndromes: When should they be considered in the work-up of MDS?Best Practice & Research Clinical Haematology, 2015
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis CongenitaTransplantation and Cellular Therapy, 2013
- Individual Hematopoietic Stem Cells in Human Bone Marrow of Patients with Aplastic Anemia or Myelodysplastic Syndrome Stably Give Rise to Limited Cell LineagesStem Cells, 2013